MIOL implantation in paediatric cases

Article

A review of surgical results demonstrate safety

"While the presence of binocular clear media is mandatory for complete vision rehabilitation and amblyopia treatment, the choice of lens for a child is of importance as it impacts the development of their vision and has a potentially life-long effect," she continued. "Behavioural difficulties in the wearing of glasses or contact lenses are frequent in children, especially those with a syndromic cataract. The use of MIOL in children, with the advantage of correcting both distance and near vision, is thus highly attractive."

However, Dr Abouzeid noted that it can be difficult to assess the occurrence of well known side effects of MIOLs in children, such as low contrast sensitivity, presence of halos or glare, or their influence on visual development, amblyopia and its treatment outcomes. "Refractive shift with eye growth is another major issue to be considered in the choice of the best suitable lens for a child, especially in the case of MIOLs, and it is because of these factors that MIOL implantation is controversial in paediatric cases," she advised..

To evaluate the implantation of a MIOL in children Dr Abouzeid and colleagues reviewed 34 eyes of 26 patients who had all undergone surgery at the same institute and had been followed up for at least 1 year. "We reviewed the files of the operated patients and created a database with selected main criteria to study that would reflect the outcomes. We selected cases with a minimum of 12 months follow-up to appropriately study complications," Dr Abouzeid added.

The mean age of the patients was 7.87 ± 4.8 years and out of the study group there were 14 patients that underwent unilateral surgery. All patients were implanted with the same lens (Alcon, model SN6AD3, Alcon Laboratories Inc., Fort Worth, Texas, USA). "We chose this lens because of the large studies available attesting its safety and high refractive quality as well as for the fact that it carries on blue light filtration and provides +3 dioptres equivalent in glasses, which may be useful for children," she explained.

Spearman correlations were calculated for all cases between the preop visual acuity and postop stereopsis, the patient's age at surgery and postop stereopsis as well as the change in visual acuity and the age at surgery. Additionally, bilateral and unilateral implantation procedures were treated separately in these calculations.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.